Abstract : Pterygium is a conjunctival tissue hyperplastic degenerative process in form of triangular fibrovascular tissue, growing on conjunctival towards and infiltrating corneal surface. Inflammation process on ocular surface was believed to be involved in the recurrence of pterygium tissue post excision surgery. Recent years, the effect of local injection of triamcinolone and bevacizumab in recurrence of pterygium have been studied but remain with unsatisfied results. This study aimed to analyze changes of expression of messenger RNA (mRNA) interleukin-1 (IL-1) after injection of 20 mg of triamcinolone and 2.5 mg of bevacizumab subconjunctiva in pterygium patient. Methods: Fifteen eyes with stage II primary pterygia were included in this study. Patients were randomized into three groups; the triamcinolone group, bevacizumab group and placebo group. Subconjunctival of 20 mg of Triamcinolone or 2.5 mg of bevacizumab or placebo (depend on group) were injected one week before surgery. All subject was done pterygium surgery with autograft technique. Main outcome measures included changes of mRNA IL-1 expression between Triamcinolone group, Bevacizumab group and placebo group. One month follow up was completed in fifteen eyes. Blood level changes of mRNA IL-1 expression in bevacizumab group was 4.09 ± 0.52, triamcinolone group was 3.40 ± 2.62, and placebo group was 1.08 ± 1.48, respectively (p = 0.04). Comparison between group, there are significant effect between bevacizumab group and placebo group (p= 0.00), and no significant effect in triamcinolone group (p = 0.06). Conclusion: Subconjunctival injection of Bevacizumab and Triamcinolone before surgery effective in suppressing inflammation in pterygium